The effects of CHF6467, a new mutated form of NGF, on cell models of human glioblastoma. A comparison with wild-type NGF.

Abstract

CHF6467 is a mutated form of human recombinant nerve growth factor (NGF). The mutation selectively disrupts the binding of NGF to its p75NTR receptor while maintaining the affinity toward TrkA receptor. Because of such different profile of receptor interaction, CHF6467 maintains unaltered the neurotrophic and neuroprotective properties of wild-type NGF but shows reduced algogenic activity.In this study, we investigated the effects of CHF6467 on mortality, proliferation, cell-damage and migration in three human glioblastoma cell lines (U87MG, T98G, LN18), and in the rat astrocytoma C6 cells. Both CHF6467 and wild-type NGF, given in the range 1-50 ng/ml, did not modify cell proliferation, metabolism and migration, as well as the number of live/dead cells.The present in vitro data are predictive of a lack of tumorigenic activity by both wild-type NGF and CHF6467 on these cell types in vivo, and warrant for CHF6467 further clinical development.

• Authors: Lucia Lisi, Gabriella Maria Pia Ciotti, Marta Chiavari, Maria Martire, Pierluigi Navarra
• Journal: Growth factors (Chur, Switzerland) (Growth Factors) Vol. 40 Issue 1-2 Pg. 37-45 (06 2022) ISSN: 1029-2292 [Electronic] England
• PMID: 35442129 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Receptors, Nerve Growth Factor
• Nerve Growth Factor
• Receptor, trkA

Topics

• Animals
• Cell Line
• Glioblastoma (genetics)
• Humans
• Nerve Growth Factor (genetics, metabolism)
• Rats
• Receptor, trkA (genetics, metabolism)
• Receptors, Nerve Growth Factor (genetics, metabolism)